Skip to content
The Policy VaultThe Policy Vault

Venclexta (venetoclax) — Medica

Myeloproliferative Neoplasm

Initial criteria

  • age ≥ 18 years
  • accelerated or blast phase disease
  • used in combination with azacitidine OR decitabine

Approval duration

1 year